A Phase 3 interventional study of liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 185 sites in 36 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-07-02.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 55th largest by enrollment, is one of 21 that started in 2012, is one of 45 in phase 3, and was the 56th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Mansa · Sites in United States
Ages 10+
Biolingus · Sites in Hong Kong
Ages 18–65
RenJi Hospital · Sites in China
Ages 18–65
University of Virginia · Sites in United States
Ages 21–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 46 · Phase 4 48
First in 1999; this study’s year is marked. 21 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 151 interventional studies. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 151 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 251st largest by enrollment of the 428 interventional ones that give a count, is one of 24 that started in 2012, is one of 187 in phase 3, and was the 290th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing liraglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03883412University of VirginiaEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted globally. The aim of this trial is to assess the efficacy and safety of liraglutide in the paediatric population in order to potentially address the unmet need for treatment of children and adolescents with type 2 diabetes.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 135 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria: - Children and adolescents between the ages of 10-16 years. Subjects cannot turn 17 years and 11 months before the end of treatment (52 weeks) - Diagnosis of type 2 diabetes mellitus and treated for at least 30 days with: diet and exercise alone, diet and exercise in combination with metformin monotherapy, diet and exercise in combination with metformin and a stable (Stable is defined as basal insulin adjustments up to 15%) dose of basal insulin, diet and exercise in combination with a stable (Stable is defined as basal insulin adjustments up to 15%) dose of basal insulin - : 7.0-11% (inclusive) if diet and exercise treated or 6.5-11% (inclusive) if treated with metformin as monotherapy, basal insulin as monotherapy or metformin and basal insulin in combination - (BMI) above 85% percentile of the general age and gender matched population Exclusion Criteria: - Type 1 diabetes - Maturity onset diabetes of the young (MODY) - Use of any antidiabetic agent other than metformin and/or basal insulin within 90 days prior to screening - Recurrent severe hypoglycaemia or hypoglycaemic unawareness as judged by the investigator - History of chronic pancreatitis or idiopathic acute pancreatitis - Any disorder, except for conditions associated with type 2 diabetes history which in the investigator's opinion could interfere with results of the trial - Uncontrolled hypertension, treated or untreated above 99th percentile for age and gender in children - Known or suspected abuse of alcohol or drugs/narcotics
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: liraglutide · Drug: metformin
Drug: placebo · Drug: metformin
Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks. Subjects will continue treatment in a 26 week open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.
Change in HbA1c (Glycosylated Haemoglobin)
Change in HbA1c from baseline to week 26. All available data were used for the primary analysis, including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Change From Baseline in Fasting Plasma Glucose (FPG)
Change in FPG from baseline to week 26. All available data were used for the analysis, including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Number of Subjects Having HbA1c Below 7.0%
Percentage of subjects having HbA1c \<7.0%. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 26
Change From Baseline in Body Mass Index (BMI) Standard Deviation Score (SDS)
Change in BMI SDS from baseline to week 26. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the world health organisation (WHO) Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Number of Subjects Having HbA1c Below 7.0%
Number of subjects achieving HbA1c \<7.0% after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 52
Number of Subjects Having HbA1c Maximum 6.5%
Number of subjects achieving HbA1c \<=6.5% after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 26
Number of Subjects Having HbA1c Maximum 6.5%
Number of subjects achieving HbA1c \<=6.5% after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 52
Number of Subjects Having HbA1c Below 7.0% Without Severe or Minor Hypoglycaemic Episodes
Number of subjects achieving HbA1c \<7.0% without severe or minor hypoglycaemic episodes after 26 weeks. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemia was defined as meeting either of the below criteria: 1. an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL), and which was handled by the subject him/herself 2. any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose value \<3.1 mmol/L (56 mg/dL) All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 26
Number of Subjects Having HbA1c Below 7.0% Without Severe or Minor Hypoglycaemic Episodes
Number of subjects achieving HbA1c \<7.0% without severe or minor hypoglycaemic episodes after 52 weeks. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemia was defined as meeting either of the below criteria: 1. an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL), and which was handled by the subject him/herself 2. any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose value \<3.1 mmol/L (56 mg/dL) All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 52
Number of Subjects Having HbA1c Below 7.5%
Number of subjects achieving HbA1c \<7.5% after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 26
Number of Subjects Having HbA1c Below 7.5%
Number of subjects achieving HbA1c \<7.5% after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 52
Change in HbA1c
Change in HbA1c from baseline to week 52. All available data were used for the analysis, including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Change in FPG
Change in FPG from baseline to week 52. All available data were used for the analysis, including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Change in Mean 7-point Self-measured Plasma Glucose
Change in mean 7-point self-measured plasma glucose after 26 weeks. Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Mean 7-point SMPG was defined as the area under the profile (calculated using the trapezoidal method) divided by time. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Change From Baseline in 7-point Self-measured Plasma Glucose
Change in mean 7-point self-measured plasma glucose after 52 weeks. Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Mean 7-point SMPG was defined as the area under the profile (calculated using the trapezoidal method) divided by time. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Change in Post-prandial Increments (From Before Meal to 90 Min After Breakfast, Lunch, and Dinner)
Change in post-prandial increments (from before meal to 90 min after breakfast, lunch, and dinner) after 26 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Change in Post-prandial Increments (From Before Meal to 90 Min After Breakfast, Lunch, and Dinner)
Change in post-prandial increments (from before meal to 90 min after breakfast, lunch, and dinner) after 52 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Change in Mean Post-prandial Increment Across All Three Meals (Breakfast, Lunch, and Dinner)
Change in mean post-prandial increment across all three meals (breakfast, lunch, and dinner) after 26 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Change in Mean Post-prandial Increment Across All Three Meals (Breakfast, Lunch, and Dinner)
Change in mean post-prandial increment across all three meals (breakfast, lunch, and dinner) after 52 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Change From Baseline in Body Weight
Change from baseline in body weight after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Change From Baseline in Body Weight
Change from baseline in body weight after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Change From Baseline in BMI Standard Deviation Score (SDS)
Change in BMI SDS from baseline to week 52. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Change in Blood Pressure (Systolic and Diastolic Blood Pressure)
Change in blood pressure (systolic and diastolic blood pressure) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Change in Blood Pressure (Systolic and Diastolic Blood Pressure)
Change in blood pressure (systolic and diastolic blood pressure) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Ratio to Baseline: Fasting Insulin
Ratio to baseline (fasting insulin) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Ratio to Baseline: Fasting Insulin
Ratio to baseline (fasting insulin) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Ratio to Baseline: Fasting Pro-insulin
Ratio to baseline (fasting pro-insulin) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Ratio to Baseline: Fasting Pro-insulin
Ratio to baseline (fasting pro-insulin) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Ratio to Baseline: Pro-insulin/Insulin Ratio
Ratio to baseline (Pro-insulin/insulin ratio) after week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Ratio to Baseline: Pro-insulin/Insulin Ratio
Ratio to baseline (Pro-insulin/insulin ratio) after week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Ratio to Baseline: Fasting Glucagon
Ratio to baseline (fasting glucagon) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Ratio to Baseline: Fasting Glucagon
Ratio to baseline (fasting glucagon) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Ratio to Baseline: Fasting C-peptide
Ratio to baseline (fasting C-peptide) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Ratio to Baseline: Fasting C-peptide
Ratio to baseline (fasting C-peptide) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Ratio to Baseline: Homeostasis Model Assessment of Beta-cell Function (HOMA-B)
Ratio to baseline (HOMA-B) after 26 weeks. HOMA-B is an index of beta-cell function and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Ratio to Baseline: HOMA-B
Ratio to baseline (HOMA-B) after 52 weeks. HOMA-B is an index of beta-cell function and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Ratio to Baseline: Homeostasis Model Assessment as an Index of Insulin Resistance (HOMA-IR)
Ratio to baseline (HOMA-IR) after 26 weeks. HOMA-IR is an index of insulin resistance and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Ratio to Baseline: HOMA-IR
Ratio to baseline (HOMA-IR) after 52 weeks. HOMA-IR is an index of insulin resistance and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Ratio to Baseline: Total Cholesterol
Ratio to baseline (total cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Ratio to Baseline: Total Cholesterol
Ratio to baseline (total cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Ratio to Baseline: Low Density Lipoprotein (LDL) Cholesterol
Ratio to baseline (LDL cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Ratio to Baseline: LDL Cholesterol
Ratio to baseline (LDL cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Ratio to Baseline: Very Low-density Lipoprotein (VLDL) Cholesterol
Ratio to baseline (VLDL cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Ratio to Baseline: VLDL Cholesterol
Ratio to baseline (VLDL cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Ratio to Baseline: High-density Lipoprotein (HDL) Cholesterol
Ratio to baseline (HDL cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Ratio to Baseline: HDL Cholesterol
Ratio to baseline (HDL cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Ratio to Baseline: Triglycerides
Ratio to baseline (triglycerides) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Ratio to Baseline: Triglycerides
Ratio to baseline (triglycerides) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Ratio to Baseline: Free Fatty Acids
Ratio to baseline (free fatty acids) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Ratio to Baseline: Free Fatty Acids
Ratio to baseline (free fatty acids) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Change From Baseline in Pulse
Change from baseline in pulse 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Change From Baseline in Pulse
Change from baseline in pulse 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Change From Baseline in Height SDS
Change in height SDS from baseline to week 26. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Change From Baseline in Height SDS
Change in height SDS from baseline to week 52. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Change in Bone Age Assessment (X-ray of Left Hand and Wrist)
Change in bone age from baseline to week 52. If the baseline (week 0) bone age assessment indicated that all epiphyses were fused, then the assessment was not repeated at week 52.
Time frame: Week 0, week 52
Pubertal Assessment/Progression (Tanner Staging)
Pubertal development was assessed in 3 areas (breast, penis and pubic hair development) by the Tanner staging in accordance with stages I-V. The Tanner staging assessment was no longer required to be performed once a subject reached the Tanner stage V, as judged by the investigator. Reported results are number of participants at different Tanner stages at week 0, week 26 and week 52.
Time frame: Week 0, week 26, week 52
Growth (Height Velocity)
Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days.
Time frame: Week 0, week 26
Growth (Height Velocity)
Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days.
Time frame: Week 0, week 52
Height Velocity SDS
Height velocity SDS scores at week 26. Height velocity is change in height per year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 26
Height Velocity SDS
Height velocity SDS scores at week 52. Height velocity is change in height per year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
Time frame: Week 0, week 52
Number of Hypoglycaemic Episodes
Total number of hypoglycaemic episodes according to American Diabetes Association (ADA) classification from baseline (week 0) to week 26.
Time frame: 0-26 weeks
Number of Hypoglycaemic Episodes
Total number of hypoglycaemic episodes according to American Diabetes Association (ADA) classification from baseline (week 0) to week 52.
Time frame: 0-52 weeks
Number of Adverse Events (Week 0-26)
Total number of adverse events during 26 weeks.
Time frame: 0-26 weeks
Number of Adverse Events (Week 0-52)
Total number of adverse events during entire treatment period.
Time frame: 0-52 weeks
Number of Serious Adverse Events (Week 0-26)
Total number of serious adverse events during 26 weeks.
Time frame: 0-26 weeks
Number of Serious Adverse Events (Week 0-52)
Total number of serious adverse events during entire treatment period.
Time frame: 0-52 weeks
Number of Adverse Events (Week 53-104)
This outcome is applicable only for the Liraglutide 1.8 mg treatment arm. Number of adverse events reported during follow-up 1 (week 53 to 104).
Time frame: Week 53-104
Number of Serious Adverse Events (Week 53-104)
This outcome is applicable only for the Liraglutide 1.8 mg treatment arm. Number of serious adverse events reported during follow up 1 (week 53 to 104).
Time frame: Weeks 53-104
Growth (Height Velocity)- Week 104
Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.
Time frame: Week 0, week 104
Height Velocity SDS- Week 104
The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.
Time frame: Week 0, week 104
Change From Week 52 in Height SDS- Week 104
Change in height SDS from week 52 to week 104. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.
Time frame: Week 52, week 104
Change in Pubertal Assessment/Progression (Tanner Staging)- Week 104
Pubertal development was assessed in 3 areas (breast, penis and pubic hair development) by the Tanner staging in accordance with stages I-V, where stage I represents "pre-adoloscent development" and stage V represents "pubertal development equivalent to that of an adult". The Tanner staging assessment was no longer required to be performed once a subject reached the Tanner stage V, as judged by the investigator. Reported results are number of subjects at different Tanner stages at week 52 and week 104. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.
Time frame: Week 52, week 104
Change From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 104
Change in bone age from week 52 to week 104. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.
Time frame: Week 52, week 104
Number of Adverse Events (Week 53-156)
This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm. Number of adverse events reported during the follow-up period (weeks 53 to 156).
Time frame: Week 53-156
Number of Serious Adverse Events (Week 53-156)
This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm. Number of serious adverse events reported during the follow up period (week 53 to 156).
Time frame: Weeks 53-156
Growth (Height Velocity)- Week 156
Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.
Time frame: Week 0, week 156
Height Velocity SDS- Week 156
The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.
Time frame: Week 0, week 156
Change From Week 52 in Height SDS- Week 156
Change in height SDS from week 52 to week 156. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.
Time frame: Week 52, week 156
Change in Pubertal Assessment/Progression (Tanner Staging)- Week 156
Pubertal development was assessed in 3 areas (breast, penis and pubic hair development) by the Tanner staging in accordance with stages I-V, where stage I represents "pre-adoloscent development" and stage V represents "pubertal development equivalent to that of an adult". The Tanner staging assessment was no longer required to be performed once a subject reached the Tanner stage V, as judged by the investigator. Reported results are number of subjects at different Tanner stages at week 52 and week 156. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.
Time frame: Week 52, week 156
Change From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 156
Change in bone age from week 52 to week 156. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.
Time frame: Week 52, week 156
The trial was conducted at 84 sites in 25 countries.
| Milestone | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Started | 66 | 69 |
| Exposed | 66 | 68 |
| Completed | 56 | 53 |
| Not completed | 10 | 16 |
| Withdrew: Withdrawal criteria | 6 | 8 |
| Withdrew: Non-compliance | 4 | 4 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Unclassified | 0 | 3 |
| Milestone | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Started | 52 | 0 |
| Completed | 50 | 0 |
| Not completed | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Started | 48 | 0 |
| Completed | 48 | 0 |
| Not completed | 0 | 0 |
Change in HbA1c from baseline to week 26. All available data were used for the primary analysis, including data collected after treatment discontinuation and initiation of rescue medication.
| Percentage of HbA1c | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change in HbA1c (Glycosylated Haemoglobin) | -0.643 ± 0.215 | 0.415 ± 0.216 |
Change in FPG from baseline to week 26. All available data were used for the analysis, including data collected after treatment discontinuation and initiation of rescue medication.
| mmol/L | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | -1.076 ± 0.436 | 0.801 ± 0.449 |
Percentage of subjects having HbA1c \<7.0%. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| Percentage of subjects | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Number of Subjects Having HbA1c Below 7.0% | 63.7 | 36.5 |
Change in BMI SDS from baseline to week 26. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the world health organisation (WHO) Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| SDS score | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change From Baseline in Body Mass Index (BMI) Standard Deviation Score (SDS) | -0.254 ± 0.039 | -0.208 ± 0.039 |
Number of subjects achieving HbA1c \<7.0% after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| Participants | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Yes | 27 | 16 |
| No | 29 | 36 |
Number of subjects achieving HbA1c \<=6.5% after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| Participants | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Yes | 28 | 19 |
| No | 31 | 39 |
Number of subjects achieving HbA1c \<=6.5% after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| Participants | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Yes | 25 | 13 |
| No | 31 | 39 |
Number of subjects achieving HbA1c \<7.0% without severe or minor hypoglycaemic episodes after 26 weeks. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemia was defined as meeting either of the below criteria: 1. an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL), and which was handled by the subject him/herself 2. any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose value \<3.1 mmol/L (56 mg/dL) All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| Participants | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Yes | 31 | 21 |
| No | 28 | 37 |
Number of subjects achieving HbA1c \<7.0% without severe or minor hypoglycaemic episodes after 52 weeks. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemia was defined as meeting either of the below criteria: 1. an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL), and which was handled by the subject him/herself 2. any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose value \<3.1 mmol/L (56 mg/dL) All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| Participants | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Yes | 22 | 16 |
| No | 34 | 36 |
Number of subjects achieving HbA1c \<7.5% after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| Participants | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Yes | 43 | 29 |
| No | 16 | 29 |
Number of subjects achieving HbA1c \<7.5% after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| Participants | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Yes | 36 | 23 |
| No | 20 | 29 |
Change in HbA1c from baseline to week 52. All available data were used for the analysis, including data collected after treatment discontinuation and initiation of rescue medication.
| percentage of HbA1c | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change in HbA1c | -0.732 ± 1.423 | 0.677 ± 1.523 |
Change in FPG from baseline to week 52. All available data were used for the analysis, including data collected after treatment discontinuation and initiation of rescue medication.
| mmol/L | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change in FPG | -1.627 ± 2.717 | 0.983 ± 3.954 |
Change in mean 7-point self-measured plasma glucose after 26 weeks. Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Mean 7-point SMPG was defined as the area under the profile (calculated using the trapezoidal method) divided by time. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| mmol/L | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change in Mean 7-point Self-measured Plasma Glucose | -2.384 ± 2.638 | 0.198 ± 2.056 |
Change in mean 7-point self-measured plasma glucose after 52 weeks. Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Mean 7-point SMPG was defined as the area under the profile (calculated using the trapezoidal method) divided by time. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| mmol/L | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change From Baseline in 7-point Self-measured Plasma Glucose | -2.309 ± 2.968 | -0.748 ± 1.944 |
Change in post-prandial increments (from before meal to 90 min after breakfast, lunch, and dinner) after 26 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| mmol/L | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Breakfast | -1.528 ± 3.168 | -0.319 ± 3.228 |
| Lunch | -0.358 ± 3.281 | -0.658 ± 3.421 |
| Dinner | 0.397 ± 3.790 | -0.226 ± 2.806 |
Change in post-prandial increments (from before meal to 90 min after breakfast, lunch, and dinner) after 52 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| mmol/L | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Breakfast | -1.802 ± 3.338 | 0.053 ± 2.124 |
| Lunch | -0.735 ± 3.809 | -1.219 ± 3.038 |
| Dinner | -0.028 ± 3.501 | -0.195 ± 2.803 |
Change in mean post-prandial increment across all three meals (breakfast, lunch, and dinner) after 26 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| mmol/L | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change in Mean Post-prandial Increment Across All Three Meals (Breakfast, Lunch, and Dinner) | -0.428 ± 2.172 | -0.362 ± 1.733 |
Change in mean post-prandial increment across all three meals (breakfast, lunch, and dinner) after 52 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| mmol/L | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change in Mean Post-prandial Increment Across All Three Meals (Breakfast, Lunch, and Dinner) | -0.747 ± 2.245 | -0.397 ± 1.594 |
Change from baseline in body weight after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| kg | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change From Baseline in Body Weight | -2.48 ± 5.59 | -0.87 ± 3.84 |
Change from baseline in body weight after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| kg | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change From Baseline in Body Weight | -2.27 ± 8.05 | 1.02 ± 4.64 |
Change in BMI SDS from baseline to week 52. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| SDS score | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change From Baseline in BMI Standard Deviation Score (SDS) | -0.361 ± 0.542 | -0.166 ± 0.330 |
Change in blood pressure (systolic and diastolic blood pressure) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| mmHg | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Systolic Blood Pressure | -1.65 ± 10.69 | 0.03 ± 10.05 |
| Diastolic Blood Pressure | -1.27 ± 8.39 | 0.97 ± 7.65 |
Change in blood pressure (systolic and diastolic blood pressure) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| mmHg | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Systolic Blood Pressure | -0.77 ± 11.77 | 2.81 ± 8.48 |
| Diastolic Blood Pressure | 0.46 ± 10.01 | 1.83 ± 7.26 |
Ratio to baseline (fasting insulin) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Fasting Insulin | 0.9 ± 76.4 | 1.0 ± 77.9 |
Ratio to baseline (fasting insulin) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Fasting Insulin | 1.0 ± 80.6 | 1.1 ± 142.8 |
Ratio to baseline (fasting pro-insulin) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Fasting Pro-insulin | 0.62 ± 110.3 | 0.88 ± 131.6 |
Ratio to baseline (fasting pro-insulin) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Fasting Pro-insulin | 0.62 ± 118.0 | 0.79 ± 121.0 |
Ratio to baseline (Pro-insulin/insulin ratio) after week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Pro-insulin/Insulin Ratio | 0.690 ± 102.4 | 0.923 ± 197.6 |
Ratio to baseline (Pro-insulin/insulin ratio) after week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Pro-insulin/Insulin Ratio | 0.689 ± 106.6 | 0.770 ± 225.1 |
Ratio to baseline (fasting glucagon) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Fasting Glucagon | 0.98 ± 29.3 | 1.03 ± 32.4 |
Ratio to baseline (fasting glucagon) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Fasting Glucagon | 1.01 ± 35.0 | 1.05 ± 32.7 |
Ratio to baseline (fasting C-peptide) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Fasting C-peptide | 0.93 ± 39.7 | 0.84 ± 82.3 |
Ratio to baseline (fasting C-peptide) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Fasting C-peptide | 0.94 ± 40.8 | 0.83 ± 56.5 |
Ratio to baseline (HOMA-B) after 26 weeks. HOMA-B is an index of beta-cell function and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Homeostasis Model Assessment of Beta-cell Function (HOMA-B) | 1.24 ± 96.9 | 1.01 ± 119.0 |
Ratio to baseline (HOMA-B) after 52 weeks. HOMA-B is an index of beta-cell function and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: HOMA-B | 1.48 ± 105.0 | 0.93 ± 166.8 |
Ratio to baseline (HOMA-IR) after 26 weeks. HOMA-IR is an index of insulin resistance and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Homeostasis Model Assessment as an Index of Insulin Resistance (HOMA-IR) | 0.73 ± 80.5 | 0.98 ± 80.8 |
Ratio to baseline (HOMA-IR) after 52 weeks. HOMA-IR is an index of insulin resistance and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: HOMA-IR | 0.82 ± 86.4 | 1.08 ± 140.3 |
Ratio to baseline (total cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Total Cholesterol | 0.975 ± 17.7 | 1.008 ± 13.3 |
Ratio to baseline (total cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Total Cholesterol | 1.013 ± 21.0 | 1.026 ± 13.5 |
Ratio to baseline (LDL cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Low Density Lipoprotein (LDL) Cholesterol | 0.998 ± 24.8 | 0.993 ± 20.4 |
Ratio to baseline (LDL cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: LDL Cholesterol | 1.042 ± 46.3 | 1.035 ± 21.5 |
Ratio to baseline (VLDL cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Very Low-density Lipoprotein (VLDL) Cholesterol | 0.890 ± 51.6 | 1.035 ± 35.3 |
Ratio to baseline (VLDL cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: VLDL Cholesterol | 0.983 ± 48.4 | 1.003 ± 45.5 |
Ratio to baseline (HDL cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: High-density Lipoprotein (HDL) Cholesterol | 0.997 ± 18.7 | 0.981 ± 16.3 |
Ratio to baseline (HDL cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: HDL Cholesterol | 1.028 ± 16.0 | 1.000 ± 18.8 |
Ratio to baseline (triglycerides) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Triglycerides | 0.894 ± 50.6 | 1.038 ± 36.0 |
Ratio to baseline (triglycerides) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Triglycerides | 0.964 ± 50.5 | 1.036 ± 48.4 |
Ratio to baseline (free fatty acids) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Free Fatty Acids | 1.023 ± 67.4 | 0.985 ± 47.5 |
Ratio to baseline (free fatty acids) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| ratio | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Ratio to Baseline: Free Fatty Acids | 0.928 ± 58.2 | 0.868 ± 54.8 |
Change from baseline in pulse 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| beats/minute | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change From Baseline in Pulse | 1.40 ± 10.89 | 0.33 ± 7.69 |
Change from baseline in pulse 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| beats/minute | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change From Baseline in Pulse | -0.05 ± 10.39 | -0.28 ± 7.88 |
Change in height SDS from baseline to week 26. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| SDS score | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change From Baseline in Height SDS | -0.100 ± 0.133 | -0.042 ± 0.210 |
Change in height SDS from baseline to week 52. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| SDS score | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change From Baseline in Height SDS | -0.192 ± 0.223 | -0.134 ± 0.293 |
Change in bone age from baseline to week 52. If the baseline (week 0) bone age assessment indicated that all epiphyses were fused, then the assessment was not repeated at week 52.
| years | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Change in Bone Age Assessment (X-ray of Left Hand and Wrist) | 1.197 ± 0.899 | 1.088 ± 0.889 |
Pubertal development was assessed in 3 areas (breast, penis and pubic hair development) by the Tanner staging in accordance with stages I-V. The Tanner staging assessment was no longer required to be performed once a subject reached the Tanner stage V, as judged by the investigator. Reported results are number of participants at different Tanner stages at week 0, week 26 and week 52.
| Participants | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Female - Breast development - Week 0 — Stage I | 1 | 0 |
| Female - Breast development - Week 0 — Stage II | 2 | 0 |
| Female - Breast development - Week 0 — Stage III | 4 | 10 |
| Female - Breast development - Week 0 — Stage IV | 8 | 9 |
| Female - Breast development - Week 0 — Stage V | 26 | 23 |
| Female - Breast development - Week 26 — Stage I | 0 | 0 |
| Female - Breast development - Week 26 — Stage II | 1 | 0 |
| Female - Breast development - Week 26 — Stage III | 2 | 4 |
| Female - Breast development - Week 26 — Stage IV | 5 | 10 |
| Female - Breast development - Week 26 — Stage V | 29 | 22 |
| Female - Breast development - Week 52 — Stage I | 0 | 0 |
| Female - Breast development - Week 52 — Stage II | 0 | 0 |
| Female - Breast development - Week 52 — Stage III | 1 | 2 |
| Female - Breast development - Week 52 — Stage IV | 5 | 9 |
| Female - Breast development - Week 52 — Stage V | 27 | 22 |
| Male - Penis Development - Week 0 — Stage I | 2 | 0 |
| Male - Penis Development - Week 0 — Stage II | 1 | 3 |
| Male - Penis Development - Week 0 — Stage III | 2 | 6 |
| Male - Penis Development - Week 0 — Stage IV | 9 | 11 |
| Male - Penis Development - Week 0 — Stage V | 11 | 6 |
| Male - Penis Development - Week 26 — Stage I | 2 | 0 |
| Male - Penis Development - Week 26 — Stage II | 1 | 1 |
| Male - Penis Development - Week 26 — Stage III | 2 | 4 |
| Male - Penis Development - Week 26 — Stage IV | 7 | 8 |
| Male - Penis Development - Week 26 — Stage V | 13 | 10 |
| Male - Penis Development - Week 52 — Stage I | 1 | 0 |
| Male - Penis Development - Week 52 — Stage II | 2 | 0 |
| Male - Penis Development - Week 52 — Stage III | 0 | 2 |
| Male - Penis Development - Week 52 — Stage IV | 7 | 6 |
| Male - Penis Development - Week 52 — Stage V | 15 | 13 |
| Pubic Hair Development - Week 0 — Stage I | 3 | 3 |
| Pubic Hair Development - Week 0 — Stage II | 3 | 0 |
| Pubic Hair Development - Week 0 — Stage III | 8 | 10 |
| Pubic Hair Development - Week 0 — Stage IV | 14 | 25 |
| Pubic Hair Development - Week 0 — Stage V | 38 | 29 |
| Pubic Hair Development - Week 26 — Stage I | 3 | 0 |
| Pubic Hair Development - Week 26 — Stage II | 0 | 2 |
| Pubic Hair Development - Week 26 — Stage III | 5 | 4 |
| Pubic Hair Development - Week 26 — Stage IV | 11 | 18 |
| Pubic Hair Development - Week 26 — Stage V | 43 | 34 |
| Pubic Hair Development - Week 52 — Stage I | 1 | 0 |
| Pubic Hair Development - Week 52 — Stage II | 1 | 0 |
| Pubic Hair Development - Week 52 — Stage III | 4 | 2 |
| Pubic Hair Development - Week 52 — Stage IV | 8 | 17 |
| Pubic Hair Development - Week 52 — Stage V | 43 | 34 |
Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days.
| cm/year | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Growth (Height Velocity) | 1.633 ± 2.016 | 2.486 ± 2.834 |
Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days.
| cm/year | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Growth (Height Velocity) | 1.345 ± 1.730 | 1.817 ± 2.043 |
Height velocity SDS scores at week 26. Height velocity is change in height per year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| SDS score | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Height Velocity SDS | -1.24 ± 1.695 | -0.557 ± 2.058 |
Height velocity SDS scores at week 52. Height velocity is change in height per year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.
| SDS score | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Height Velocity SDS | -0.887 ± 1.460 | -0.551 ± 1.711 |
Total number of hypoglycaemic episodes according to American Diabetes Association (ADA) classification from baseline (week 0) to week 26.
| hypoglycaemic episodes | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Number of Hypoglycaemic Episodes | 92 | 43 |
Total number of hypoglycaemic episodes according to American Diabetes Association (ADA) classification from baseline (week 0) to week 52.
| hypoglycaemic episodes | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Number of Hypoglycaemic Episodes | 160 | 63 |
Total number of adverse events during 26 weeks.
| events | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Number of Adverse Events (Week 0-26) | 310 | 230 |
Total number of adverse events during entire treatment period.
| events | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Number of Adverse Events (Week 0-52) | 426 | 321 |
Total number of serious adverse events during 26 weeks.
| events | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Number of Serious Adverse Events (Week 0-26) | 7 | 4 |
Total number of serious adverse events during entire treatment period.
| events | Liraglutide 1.8 mg | Placebo |
|---|---|---|
| Number of Serious Adverse Events (Week 0-52) | 10 | 5 |
This outcome is applicable only for the Liraglutide 1.8 mg treatment arm. Number of adverse events reported during follow-up 1 (week 53 to 104).
| events | Liraglutide 1.8 mg: Follow-up 1 |
|---|---|
| Number of Adverse Events (Week 53-104) | 30 |
This outcome is applicable only for the Liraglutide 1.8 mg treatment arm. Number of serious adverse events reported during follow up 1 (week 53 to 104).
| events | Liraglutide 1.8 mg: Follow-up 1 |
|---|---|
| Number of Serious Adverse Events (Week 53-104) | 7 |
Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.
| cm/year | Liraglutide 1.8 mg: Follow-up 1 |
|---|---|
| Growth (Height Velocity)- Week 104 | 1.149 ± 1.776 |
The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.
| SDS score | Liraglutide 1.8 mg: Follow-up 1 |
|---|---|
| Height Velocity SDS- Week 104 | -0.523 ± 1.466 |
Change in height SDS from week 52 to week 104. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.
| SDS score | Liraglutide 1.8 mg: Follow-up 1 |
|---|---|
| Change From Week 52 in Height SDS- Week 104 | -0.133 ± 0.338 |
Pubertal development was assessed in 3 areas (breast, penis and pubic hair development) by the Tanner staging in accordance with stages I-V, where stage I represents "pre-adoloscent development" and stage V represents "pubertal development equivalent to that of an adult". The Tanner staging assessment was no longer required to be performed once a subject reached the Tanner stage V, as judged by the investigator. Reported results are number of subjects at different Tanner stages at week 52 and week 104. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.
| Participants | Liraglutide 1.8 mg: Follow-up 1 |
|---|---|
| Female- Breast development- Week 52 — Stage I | 0 |
| Female- Breast development- Week 52 — Stage II | 0 |
| Female- Breast development- Week 52 — Stage III | 1 |
| Female- Breast development- Week 52 — Stage IV | 5 |
| Female- Breast development- Week 52 — Stage V | 21 |
| Female- Breast development- Week 104 — Stage I | 0 |
| Female- Breast development- Week 104 — Stage II | 0 |
| Female- Breast development- Week 104 — Stage III | 0 |
| Female- Breast development- Week 104 — Stage IV | 5 |
| Female- Breast development- Week 104 — Stage V | 11 |
| Male- Penis development- Week 52 — Stage I | 1 |
| Male- Penis development- Week 52 — Stage II | 2 |
| Male- Penis development- Week 52 — Stage III | 0 |
| Male- Penis development- Week 52 — Stage IV | 7 |
| Male- Penis development- Week 52 — Stage V | 14 |
| Male- Penis development- Week 104 — Stage I | 0 |
| Male- Penis development- Week 104 — Stage II | 1 |
| Male- Penis development- Week 104 — Stage III | 0 |
| Male- Penis development- Week 104 — Stage IV | 5 |
| Male- Penis development- Week 104 — Stage V | 8 |
| Female- Pubic hair development- Week 52 — Stage I | 0 |
| Female- Pubic hair development- Week 52 — Stage II | 0 |
| Female- Pubic hair development- Week 52 — Stage III | 2 |
| Female- Pubic hair development- Week 52 — Stage IV | 2 |
| Female- Pubic hair development- Week 52 — Stage V | 22 |
| Female- Pubic hair development- Week 104 — Stage I | 0 |
| Female- Pubic hair development- Week 104 — Stage II | 0 |
| Female- Pubic hair development- Week 104 — Stage III | 1 |
| Female- Pubic hair development- Week 104 — Stage IV | 2 |
| Female- Pubic hair development- Week 104 — Stage V | 13 |
| Male- Pubic hair development- Week 52 — Stage I | 1 |
| Male- Pubic hair development- Week 52 — Stage II | 1 |
| Male- Pubic hair development- Week 52 — Stage III | 2 |
| Male- Pubic hair development- Week 52 — Stage IV | 6 |
| Male- Pubic hair development- Week 52 — Stage V | 14 |
| Male- Pubic hair development- Week 104 — Stage I | 0 |
| Male- Pubic hair development- Week 104 — Stage II | 1 |
| Male- Pubic hair development- Week 104 — Stage III | 0 |
| Male- Pubic hair development- Week 104 — Stage IV | 4 |
| Male- Pubic hair development- Week 104 — Stage V | 9 |
Change in bone age from week 52 to week 104. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.
| Years | Liraglutide 1.8 mg: Follow-up 1 |
|---|---|
| Change From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 104 | 1.231 ± 0.992 |
This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm. Number of adverse events reported during the follow-up period (weeks 53 to 156).
| events | Liraglutide 1.8 mg: Follow-up 1 and 2 |
|---|---|
| Number of Adverse Events (Week 53-156) | 47 |
This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm. Number of serious adverse events reported during the follow up period (week 53 to 156).
| events | Liraglutide 1.8 mg: Follow-up 1 and 2 |
|---|---|
| Number of Serious Adverse Events (Week 53-156) | 9 |
Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.
| cm/year | Liraglutide 1.8 mg: Follow-up 1 and 2 |
|---|---|
| Growth (Height Velocity)- Week 156 | 1.100 ± 1.504 |
The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.
| SDS score | Liraglutide 1.8 mg: Follow-up 1 and 2 |
|---|---|
| Height Velocity SDS- Week 156 | 0.142 ± 1.156 |
Change in height SDS from week 52 to week 156. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.
| SDS score | Liraglutide 1.8 mg: Follow-up 1 and 2 |
|---|---|
| Change From Week 52 in Height SDS- Week 156 | -0.224 ± 0.446 |
Pubertal development was assessed in 3 areas (breast, penis and pubic hair development) by the Tanner staging in accordance with stages I-V, where stage I represents "pre-adoloscent development" and stage V represents "pubertal development equivalent to that of an adult". The Tanner staging assessment was no longer required to be performed once a subject reached the Tanner stage V, as judged by the investigator. Reported results are number of subjects at different Tanner stages at week 52 and week 156. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.
| Participants | Liraglutide 1.8 mg: Follow-up 1 and 2 |
|---|---|
| Female- Breast development- Week 52 — Stage I | 0 |
| Female- Breast development- Week 52 — Stage II | 0 |
| Female- Breast development- Week 52 — Stage III | 1 |
| Female- Breast development- Week 52 — Stage IV | 5 |
| Female- Breast development- Week 52 — Stage V | 21 |
| Female- Breast development- Week 156 — Stage I | 0 |
| Female- Breast development- Week 156 — Stage II | 0 |
| Female- Breast development- Week 156 — Stage III | 0 |
| Female- Breast development- Week 156 — Stage IV | 3 |
| Female- Breast development- Week 156 — Stage V | 11 |
| Male- Penis development- Week 52 — Stage I | 1 |
| Male- Penis development- Week 52 — Stage II | 2 |
| Male- Penis development- Week 52 — Stage III | 0 |
| Male- Penis development- Week 52 — Stage IV | 7 |
| Male- Penis development- Week 52 — Stage V | 14 |
| Male- Penis development- Week 156 — Stage I | 0 |
| Male- Penis development- Week 156 — Stage II | 0 |
| Male- Penis development- Week 156 — Stage III | 1 |
| Male- Penis development- Week 156 — Stage IV | 3 |
| Male- Penis development- Week 156 — Stage V | 9 |
| Female- Pubic hair development- Week 52 — Stage I | 0 |
| Female- Pubic hair development- Week 52 — Stage II | 0 |
| Female- Pubic hair development- Week 52 — Stage III | 2 |
| Female- Pubic hair development- Week 52 — Stage IV | 2 |
| Female- Pubic hair development- Week 52 — Stage V | 22 |
| Female- Pubic hair development- Week 156 — Stage I | 0 |
| Female- Pubic hair development- Week 156 — Stage II | 0 |
| Female- Pubic hair development- Week 156 — Stage III | 0 |
| Female- Pubic hair development- Week 156 — Stage IV | 2 |
| Female- Pubic hair development- Week 156 — Stage V | 11 |
| Male- Pubic hair development- Week 52 — Stage I | 1 |
| Male- Pubic hair development- Week 52 — Stage II | 1 |
| Male- Pubic hair development- Week 52 — Stage III | 2 |
| Male- Pubic hair development- Week 52 — Stage IV | 6 |
| Male- Pubic hair development- Week 52 — Stage V | 14 |
| Male- Pubic hair development- Week 156 — Stage I | 0 |
| Male- Pubic hair development- Week 156 — Stage II | 0 |
| Male- Pubic hair development- Week 156 — Stage III | 1 |
| Male- Pubic hair development- Week 156 — Stage IV | 3 |
| Male- Pubic hair development- Week 156 — Stage V | 10 |
Change in bone age from week 52 to week 156. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.
| Years | Liraglutide 1.8 mg: Follow-up 1 and 2 |
|---|---|
| Change From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 156 | 1.778 ± 1.277 |
Collected over Week 0 - 156. All presented AEs are TEAEs. A TEAE was defined as an event that had onset date on or after the first day of exposure to trial product and no later than 7 days after the last day of trial product administration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide 1.8 mg | 0/66 (0%) | 9/66 (13.6%) | 45/66 (68.2%) |
| Placebo | 0/68 (0%) | 4/68 (5.9%) | 49/68 (72.1%) |
| Liraglutide 1.8 mg: Follow-up 1 | 0/52 (0%) | 7/52 (13.5%) | 7/52 (13.5%) |
| Liraglutide 1.8 mg: Follow-up 2 | 0/48 (0%) | 2/48 (4.2%) | 1/48 (2.1%) |
| Event | Liraglutide 1.8 mg | Placebo | Liraglutide 1.8 mg: Follow-up 1 | Liraglutide 1.8 mg: Follow-up 2 |
|---|---|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 1/66 | 1/68 | 2/52 | 0/48 |
| Abdominal painGastrointestinal disorders | 1/66 | 0/68 | 0/52 | 1/48 |
| AppendicitisInfections and infestations | 0/66 | 0/68 | 0/52 | 1/48 |
| MalocclusionGastrointestinal disorders | 0/66 | 0/68 | 0/52 | 1/48 |
| ConstipationGastrointestinal disorders | 0/66 | 0/68 | 1/52 | 0/48 |
| Depressive symptomPsychiatric disorders | 0/66 | 0/68 | 1/52 | 0/48 |
| FasciotomySurgical and medical procedures | 0/66 | 0/68 | 1/52 | 0/48 |
| Metabolic surgerySurgical and medical procedures | 0/66 | 0/68 | 1/52 | 0/48 |
| Subcutaneous abscessInfections and infestations | 0/66 | 0/68 | 1/52 | 0/48 |
| Abscess neckInfections and infestations | 1/66 | 0/68 | 0/52 | 0/48 |
| Event | Liraglutide 1.8 mg | Placebo | Liraglutide 1.8 mg: Follow-up 1 | Liraglutide 1.8 mg: Follow-up 2 |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 19/66 | 9/68 | 1/52 | 0/48 |
| NasopharyngitisInfections and infestations | 11/66 | 19/68 | 2/52 | 0/48 |
| VomitingGastrointestinal disorders | 17/66 | 6/68 | 2/52 | 0/48 |
| DiarrhoeaGastrointestinal disorders | 15/66 | 11/68 | 0/52 | 0/48 |
| HeadacheNervous system disorders | 14/66 | 13/68 | 0/52 | 0/48 |
| Abdominal painGastrointestinal disorders | 11/66 | 5/68 | 1/52 | 0/48 |
| DizzinessNervous system disorders | 8/66 | 2/68 | 0/52 | 0/48 |
| Abdominal pain upperGastrointestinal disorders | 2/66 | 8/68 | 0/52 | 0/48 |
| GastroenteritisInfections and infestations | 7/66 | 2/68 | 0/52 | 0/48 |
| Upper respiratory tract infectionInfections and infestations | 6/66 | 5/68 | 0/52 | 0/48 |
Full analysis set (FAS) - included all randomised subjects receiving at least one dose of liraglutide/placebo
| Age, Continuous(years) | Liraglutide 1.8 mg | Placebo | Total |
|---|---|---|---|
| Mean | 14.57 ± 1.73 | 14.57 ± 1.73 | 14.57 ± 1.72 |
| Sex: Female, Male(Participants) | Liraglutide 1.8 mg | Placebo | Total |
|---|---|---|---|
| Female | 41 | 42 | 83 |
| Male | 25 | 26 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Liraglutide 1.8 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 23 | 39 |
| Not Hispanic or Latino | 50 | 45 | 95 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Liraglutide 1.8 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 10 | 8 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 9 | 7 | 16 |
| White | 42 | 45 | 87 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 7 | 10 |
| Glycosylated hemoglobin (HbA1c)(percentage of HbA1c) | Liraglutide 1.8 mg | Placebo | Total |
|---|---|---|---|
| Mean | 7.87 ± 1.35 | 7.69 ± 1.34 | 7.78 ± 1.34 |
Showing the first 100 of 185 sites across 36 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Nov 2012 to primary completion in Nov 2017, 60 months.
Results were first posted in Dec 2018, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 60 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide